[Skip to Navigation]
Sign In
Views 732
Citations 0
Comment & Response
March 25, 2021

Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence

Author Affiliations
  • 1Centre for Trials Research, Cardiff University College of Biomedical and Life Sciences, Cardiff, United Kingdom
  • 2Icon Oncology, Tygerfalls, South Africa
  • 3University of Cape Town, Cape Town, South Africa
JAMA Oncol. 2021;7(5):782-783. doi:10.1001/jamaoncol.2021.0067

To the Editor We welcome the proposal in the Viewpoint by Tsai et al1 to focus clinical research and improve the use of radiotherapy in the care of patients with metastatic cancer through the PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program in their center. However, their assertion that stereotactic ablative body radiotherapy (SABR) provides survival benefit for patients with oligometastases does not reflect the evidence.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words